Add to ORKGA 76 year old male was transferred to MU for management of pneumonia and rhabdomyolysis. He gave a history of cough, green sputum, fever, chills and malaise for the past several weeks; these symptoms did not improve after a 14 day course of Augmentin
Objective: To systematically review evidence on genetic variants influencing outcomes during warfari...
Background: We have recently developed and published a pharmacogenetic algorithm, based on VKORC1, C...
The aim of the study: To show the influence of clinical and genetic factors on warfarin dosage durin...
BACKGROUND: Warfarin is the most frequently prescribed anticoagulant in North America and Europe. It...
Background: Warfarin is the most frequently prescribed anticoagulant in North America and Europe. It...
ObjectivesThis study was designed to determine whether genotype testing for patients initiating warf...
Warfarin is a potent drug that when used judiciously and monitored closely, leads to substantial red...
Warfarin and other coumarin anticoagulants are widely used clinically, but currently dosing is deter...
Pharmacogenetic testing has been researched to find genetic variability among individuals who requir...
Objective: Genetic polymorphisms of CYP2C9 and VKORC1 play major role in pharmacokinetics and pharma...
Aim:The study objectives were to investigate the association between selected CYP2C9 and VKORC1 sing...
Warfarin is still the most clinically used oral anti-coagulant despite of its narrow therapeutic ind...
Warfarin is a mainstay of therapy for conditions associated with an increased risk of thromboembolic...
Background: Warfarin is the most widely used oral anticoagulant for the prevention and treatment of ...
The genes encoding the cytochrome P450 2C9 enzyme (CYP2C9) and vitamin K-epoxide reductase complex u...
Objective: To systematically review evidence on genetic variants influencing outcomes during warfari...
Background: We have recently developed and published a pharmacogenetic algorithm, based on VKORC1, C...
The aim of the study: To show the influence of clinical and genetic factors on warfarin dosage durin...
BACKGROUND: Warfarin is the most frequently prescribed anticoagulant in North America and Europe. It...
Background: Warfarin is the most frequently prescribed anticoagulant in North America and Europe. It...
ObjectivesThis study was designed to determine whether genotype testing for patients initiating warf...
Warfarin is a potent drug that when used judiciously and monitored closely, leads to substantial red...
Warfarin and other coumarin anticoagulants are widely used clinically, but currently dosing is deter...
Pharmacogenetic testing has been researched to find genetic variability among individuals who requir...
Objective: Genetic polymorphisms of CYP2C9 and VKORC1 play major role in pharmacokinetics and pharma...
Aim:The study objectives were to investigate the association between selected CYP2C9 and VKORC1 sing...
Warfarin is still the most clinically used oral anti-coagulant despite of its narrow therapeutic ind...
Warfarin is a mainstay of therapy for conditions associated with an increased risk of thromboembolic...
Background: Warfarin is the most widely used oral anticoagulant for the prevention and treatment of ...
The genes encoding the cytochrome P450 2C9 enzyme (CYP2C9) and vitamin K-epoxide reductase complex u...
Objective: To systematically review evidence on genetic variants influencing outcomes during warfari...
Background: We have recently developed and published a pharmacogenetic algorithm, based on VKORC1, C...
The aim of the study: To show the influence of clinical and genetic factors on warfarin dosage durin...